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Abstract. In breast cancers, the large conductance Ca2+ and 
voltage sensitive K+ (BKCa) channels have been hypothesized 
to function as oncoproteins, yet it remains unclear how inhibi-
tion of channel activity impacts oncogenesis. We demonstrated 
herein that iberiotoxin (IbTX), an inhibitor of BKCa channels, 
differentially modulated the in vitro tumorigenic activities 
of hormone-independent breast cancer cells. Specifically, in 
HER-2/neu-overexpressing UACC893 cells and triple-negative 
MDA-MB-231 cells, IbTX selectively attenuated anchorage-
independent growth with concomitant downregulation 
of β-catenin as well as total and phosphorylated Akt and 
HER-2/neu. By contrast, HER-2/neu-overexpressing SK-BR-3 
cells were insensitive to IbTX. Molecular analyses showed an 
absence of β-catenin and a dose-dependent upregulation of 
total and phosphorylated Akt and HER-2/neu in these cells. 
Taken together, these studies identify β-catenin as a putative 
modulator of the inhibitory actions of IbTX in sensitive breast 
cancer cells.
Introduction
The large conductance calcium and voltage activated potassium 
(BKCa) channels have been shown to function as oncogenes in 
certain cancers (1-4). BKCa channels generate vast amounts 
of outward K+ currents and therefore are powerful modulators 
of the transmembrane potential of a cell. BKCa channels are 
overexpressed in many types of cancers via gene amplifica-
tion, alternative splicing or increased protein half-life (5-8). In 
addition, neoplastic BKCa channels may possess augmented 
sensitivity to Ca2+ and voltage and hence generate K+ currents 
in environments where their normal counterparts are silent (5). 
The enhanced activity of BKCa channels shifts cellular trans-
membrane potential to favor proliferative phenotypes (9). 
It is therefore plausible for BKCa channels to be considered 
putative targets for anticancer therapies. The contributions 
of BKCa channels to cancer cell migration and invasion have 
been previously demonstrated; however, their role in tumori-
genesis has not been investigated (1,3,10).
The present study presents novel findings that an inhibitor 
of BKCa channels, iberiotoxin (IbTX), selectively decreased 
anchorage-independent growth and tumorigenicity in breast 
cancer cells expressing β-catenin. Our data suggest that the 
attenuated tumorigenicity is a result of depolarizing shifts in 
cell transmembrane potential and subsequent downregulation 
of β-catenin and (phospho)Akt and HER-2/neu protein levels.
Materials and methods
Cell culture. UACC893, MDA-MB-231, SK-BR-3 and 
MCF10A cells were purchased from ATCC (Manassas, VA, 
USA). Cells were propagated in DMEM:F12 medium (Sigma-
Aldrich, St. Louis, MO, USA) supplemented with 20% fetal 
bovine serum (FBS).
Membrane potential assays. Cells were pre-loaded for 30 min 
with 2 µmol/l of a membrane potential-sensitive dye DiBAC4(3) 
(Invitrogen, Life Technologies, Carlsbad, CA, USA) in buffer 
containing (mmol/l): 20 HEPES, 140 NaCl, 2 KCl, 1 MgCl2, 
2 CaCl2, 10 glucose prior to seeding onto mouse laminin 
(Sigma-Aldrich)-coated glass bottom 35-mm tissue culture 
dishes (MatTek Corporation, Ashland, MA, USA). After 24 h, 
dishes were placed on a microscope stage pre-heated to 37˚C, 
and 10 nmol/l IbTX (Sigma-Aldrich) was added. Immediately 
following IbTX, cells were observed every minute for 20 min 
using the 488 nm laser of an LSM 510 Zeiss confocal scanning 
microscope (Zeiss, Jena, Germany). Signals from 5 to 7 regions 
of interest were quantified and averaged using LSM 510 image 
browser (Zeiss). Data were fitted using non-linear regression 
analysis and significant differences estimated by ANOVA 
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and post hoc Bonferroni's t-test (SigmaPlot; Systat Software, 
Inc., San Jose, CA, USA). A P-value ≤0.05 was considered to 
indicate a statistically significant result.
Cell viability assays. Cells were seeded into 6-well cluster 
dishes at 100,000 cells/well in DMEM:F12 supplemented 
with 20% FBS in the absence or presence of IbTX (2, 5, 10, 
25 and 50 nmol/l) for 48 h. Subsequently, cells were stained 
with trypan blue and counted using Countess Automated Cell 
Counter (Invitrogen). Experiments were repeated three times, 
and statistical differences were assessed using the Student's 
t-test.
Soft agar assays. Soft agar assays were performed as previ-
ously described (17). Briefly, following IbTX incubations as 
described for cell viability assays, cells were re-suspended 
in 0.3% agar in DMEM:F12 tissue culture medium supple-
mented with 20% FBS. Cell suspensions were seeded onto 
0.5% basal agar in 6-well cluster dishes at 1,000 cells/well. 
The cell colonies were visualized 21 days later using crystal 
violet solution (crystal violet 0.005% and citric acid 0.1%) and 
manually counted. Experiments were repeated at least twice 
in quadruplicate.
Western immunoblotting. Whole cell lysates were isolated using 
RIPA buffer containing (mmol/l) 150 NaCl, 50 Tris pH 7.4, 
1 EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS 
and protease and phosphatase inhibitors. Twenty micrograms 
of protein was separated on 4-20% Tris-HCl gels (Bio-Rad, 
Hercules, CA, USA), transferred on nitrocellulose membranes, 
and blocked in 5% BSA for 1 h at room temperature. Blots 
were then incubated with the rabbit anti-HER-2/neu antibody 
(1:500 EMD; Millipore, Billerica, MA, USA), rabbit β-catenin 
antibody (1:500), rabbit T308 phospho-Akt or total Akt anti-
body (both from Cell Signaling Technology, Danvers, MA, 
USA) overnight at 4˚C. Signals were detected with IRDye 680 
secondary antibodies (1:5,000) for 1 h at room temperature 
and visualized using LI-COR Odyssey Imaging System (both 
from LI-COR, Lincoln, NE, USA). Blots were subsequently 
incubated with mouse GAPDH antibody (1:1,000; Sigma) 
and anti-mouse IRDye 800CW secondary antibody (1:5,000; 
LI-COR) to ensure equal protein loading. N=3.
RNA isolation and qPCR. Total mRNA was isolated using the 
mirVana miRNA isolation kit (Ambion, Life Technologies, 
Carlbad, CA, USA). Following isolation, the NanoDrop M-1000 
was used to determine the concentration and the quality of 
the total RNA. A reverse transcription was performed using 
the SuperScript III First-Strand Synthesis kit (Invitrogen, Life 
Technologies) with 700 ng of total RNA. The gene expression 
was then determined with a SYBR-Green PCR assay (Applied 
Biosystems, Life Technologies, Carlbad, CA, USA) and run on 
the Applied Biosystems Model 7900 Genetic Analyzer. The 
data were normalized to the endogenous control 18s rRNA 
and analyzed using the program SDS 2.1 (Applied Biosystems, 
Life Technologies). Comparison of gene expression between 
the breast cancer MDA-MB-231, SK-BR-3 and UACC893 cells 
and the normal mammary MCF10A cells were completed 
using the ΔΔCt method. Primer sequences are available upon 
request.
Fluorescent immunocytochemistry. Cells seeded onto mouse 
laminin-coated glass bottom 35-mm tissue culture dishes 
for 24 h were fixed in 2% paraformaldehyde for 30 min and 
permeabilized in 0.1% Triton X-100 for 4 min. Cells were 
blocked in phosphate-buffered saline (PBS) supplemented 
with 5% FBS + 1% NDS for 30 min at 37˚C and incubated with 
the rabbit anti-BKCa antibody (Cell Signaling Technology) 
diluted 1:500 in 0.1% blocking buffer for 30 min at 37˚C. The 
signal was detected using the donkey anti-rabbit DyLight 488 
antibody (Jackson ImmunoResearch, West Grove, PA, USA) 
1:1,000 in 0.1% blocking buffer for 15 min at 37˚C. Cell nuclei 
were counterstained with propidium iodide (5 mg/ml 1:10,000) 
in PBS for 5 min at room temperature. Cells were visualized 
with a Zeiss 510 laser confocal microscope, and images were 
reconstructed using LSM Image Browser (both from Jena, 
Germany).
Results
BKCa channels contribute to resting transmembrane poten-
tial. We began by using RT-PCR assays to establish the levels 
of BKCa channel mRNA in several types of malignant and 
non-malignant cell lines. We detected elevated levels of BKCa 
channel mRNA in breast cancer cell lines (UACC893, SK-BR-3 
and MDA-MB-231) compared to these levels in the non-
neoplastic MCF10A cells (Fig. 1A). BKCa channel proteins, 
detected using fluorescent immunocytochemistry, formed 
typical clusters on plasma membranes in all breast cancer 
cell models (Fig. 1B). Observations of live cells loaded with 
a membrane potential sensitive dye revealed that the selective 
BKCa channel inhibitor IbTX elicited cellular depolariza-
tion indicative of a presence of functional channels. Indeed, 
IbTX depolarized cells in all three models albeit to a different 
magnitude (Fig. 1C). The UACC893 cells were significantly 
depolarized within 4 min after IbTX addition, after which 
depolarization plateaued for the duration of the experiment. 
The MDA-MB-231 cells did not acquire a plateau phase 
but rather steadily increased their transmembrane potential 
throughout the 20-min observation period. SK-BR-3 cells were 
depolarized only transiently. The emergence of depolarizing 
phases, despite differences in duration, suggests that the BKCa 
channels regulate the resting transmembrane potential of all 
three breast cancer cell lines examined.
BKCa channel inhibition selectively modulates anchorage-
independent growth. Given that BKCa channels were 
expressed and functional in our cancer cell lines, we asked 
whether pharmacological inhibition of these channels could 
lessen malignant phenotypes by impacting the ability of 
cells to proliferate, survive and/or form tumors in vitro. We 
found IbTX to attenuate de novo cell colony development in 
the UACC893 cells (Fig. 2A, left upper panel) with minimal 
inhibitory effects on anchorage-dependent cell proliferation 
(Fig. 2A, right upper panel). A similar dynamic was observed 
in the MDA-MB-231 cells where clonogenic growth (Fig. 2B, 
left middle panel) but not anchorage-dependent proliferation 
(Fig. 2B, right middle panel) was inhibited by IbTX. On the 
contrary, IbTX was ineffective in modulating colony formation 
(Fig. 2C, left lower panel) or proliferation (Fig. 2C, right lower 
panel) of SK-BR-3 cells. Thus, IbTX appeared to specifically 
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reduce the tumorigenic features of the neoplastic phenotype in 
selected breast cancer models.
BKCa channel inhibition modulates oncogenic pathways. Both 
UACC893 and SK-BR-3 cells express the HER-2/neu gene. 
Figure 1. BKCa channels regulate the transmembrane potential in breast cancer cells. (A) Breast cancer cells displayed higher levels of BKCa transcripts 
compared to benign mammary epithelial cells. Total RNA from MCF10A benign mammary epithelial cells and UACC893, MDA-MB-231 and SK-BR-3 
beast cancer cells was assayed for BKCa transcript levels using quantitative RT-PCR. Statistically significant differences vs. the MCF10A cells. N=3, P≤0.05. 
(B) BKCa channel proteins (green) were detected in UACC893 (upper panels), MDA-MB-231 (middle panels) and SK-BR-3 (lower panels) cells using fluo-
rescent immunocytochemistry. Nuclei were counterstained with propidium iodide (red) and the image series were acquired using Zeiss 510 laser confocal 
microscope. A series was reconstructed to generate three dimensional images rotated to present the lateral sides of the cells with apical surfaces facing atop of 
their respective image. MDA-MB-231 cells did not possess basal-apical differentiation and appear flat in the images. Experiments were repeated at least three 
times for each cell line. (C) IbTX differentially modulates transmembrane potential. UACC893 (upper panel), MDA-MB-231 (middle panel) and SK-BR-3 
(lower panel) cells pre-loaded with 2 µmol/l DiBac4(3) in membrane potential buffer and supplemented with 10 nmol/l IbTX were observed using a Zeiss 510 
laser confocal microscope for 20 min with images captured every minute. Average signal intensities from 5 to 7 regions of interest were calculated and plotted. 
Increased signal intensity signifies depolarization due to IbTX inhibition of BKCa channels by IbTX. Significant differences vs. start of experiment (1 min). 
N=3. IbTX, iberiotoxin.
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Thus, it was possible that disparate trends in their tumorigenic 
potential following IbTX treatment may have resulted from 
IbTX-induced modulations of oncoprotein levels. HER-2/neu 
levels decreased in the UACC893 cells at growth-inhibiting 
IbTX concentrations (Fig. 3A). By contrast, SK-BR-3 cells, 
which express both the long and short isoforms of HER-2/neu, 
demonstrated increased HER-2 levels after IbTX addition 
(Fig. 3A) (11). However, changes in HER-2/neu oncoprotein 
expression cannot account for the attenuated tumorigenic 
ability of triple-negative MDA-MB-231 cells, thus suggesting 
alternative mechanisms of growth regulation.
Upon further investigation, we found that cells with reduced 
tumorigenicity expressed β-catenin (Fig. 3B, UACC893 and 
MDA-MB-231). IbTX-resistant SK-BR-3 cells were β-catenin-
negative (data not shown); these findings are consistent with 
earlier reports (12). In UACC893 and MDA-MB-231 cells, 
both long and truncated isoforms of β-catenin were identi-
fied (Fig. 3B, β-catenin and trβ-catenin), although IbTX 
decreased expression of only the long isoform (90 kDa) (13). 
The protein kinase Akt is known to phosphorylate β-catenin 
and regulate its activity (14). We therefore examined Akt levels 
in UACC893 and MDA-MB-231 cells treated with IbTX. In 
the UACC893 cells, T308 phospho-Akt was diminished with 
increasing concentrations of IbTX; in MDA-MB-231 cells 
both total and phospho-Akt were downregulated, concordant 
with β-catenin levels. In contrast, SK-BR-3 cells demonstrated 
fluctuating levels of phospho- and total-Akt that increased 
at higher IbTX concentrations (Fig. 3C). Hence, β-catenin-
dependent pathway(s) may mediate the inhibitory actions of 
IbTX with regard to clonogenic potential in breast cancer cells.
Discussion
BKCa channels have previously been proposed as targets for 
anticancer therapies in brain and prostate cancers due to their 
presumptive pro-oncogenic roles. However, their contributions 
to the pathogenesis of hormone-independent breast cancers 
are not well understood (1). The present study implies that 
BKCa channels may exert either pro- or anti-growth effects, 
depending on the particular molecular composition of the 
cancer cell type in question.
The growth-modulating roles of BKCa channels became 
apparent in our experiments when we explored anchorage-
independent cell growth. These findings are in accord with 
Figure 2. IbTX selectively modulates anchorage-independent clonogenic growth. Cells were incubated with increasing concentrations of IbTX for 48 h, stained 
with trypan blue and counted. Cells subsequently were seeded in agar-supplemented tissue culture media. Cell colonies were visualized with crystal violet 
staining and counted. (A) In UACC893 cells, IbTX inhibited anchorage-independent colony growth in soft agar (left panel). Significant attenuation of anchorage-
dependent cell proliferation was observed only at 50 nmol/l (right panel). (B) IbTX suppressed clonogenic growth of MDA-MB-231 cells (left panel) without 
exhibiting inhibitory effects on cell proliferation (right panel). (C) IbTX did not modulate anchorage-dependent (left panel) or anchorage-independent (right 
panel) growth of SK-BR-3 cells. All assays were repeated at least twice in quadruplicate. Significant differences vs. IbTX-free controls (x-axis, 0). IbTX, 
iberiotoxin.
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earlier reports that found the BKCa channels modulated the 
tumorigenic potential of subpopulations of cancer cells (15). 
Molecular studies provided insights into the mechanisms used 
by BKCa channels to differentially regulate the tumorigenic 
properties of breast cancer cells. IbTX is a potent and selec-
tive BKCa channel inhibitor with minimal off-target effects 
at concentrations within the inhibitor's selectivity range (16). 
In addition, cells with reduced tumorigenicity, i.e. UACC893 
and MDA-MB-231, uniformly developed sustained transmem-
brane depolarization when IbTX was present. It is therefore 
plausible that suppression of oncogene(s) levels, and hence 
tumor formation, are secondary events occurring subsequent 
to sustained increases in transmembrane potential.
Notably, we also observed that BKCa channel downregu-
lation via siRNAs did not recapitulate the inhibitory actions 
of IbTX on in vitro tumorigenesis despite satisfactory trans-
fection levels (data not shown). These findings lend further 
credence to the importance of transmembrane potential for 
tumorigenesis as siRNAs are far less efficient in inhibiting K+ 
currents compared to IbTX (17). TEA, a non-selective blocker 
of K+ channels and depolarizing agent, has been shown to 
hamper in vitro endometrial tumorigenesis akin to IbTX in 
breast cancer models (18). A single discrepancy, namely the 
enhanced tumorigenic activity upon TEA washout that did not 
occur with IbTX, was due to the lower dissociation constant of 
IbTX compared to TEA, thus ensuring IbTX retention in soft 
agar (18). Hence, inhibitors with dissimilar chemical and phar-
macological profiles that share similar depolarizing actions 
can equivalently modulate anchorage-independent growth 
in disparate cancer models, suggesting that transmembrane 
potential mediates their inhibitory effects.
In the present study, tumor cell lines that showed 
suppressed in vitro colony growth in the presence of IbTX 
shared positivity for β-catenin. Thus, it is possible that a 
canonical Wnt pathway could mediate the anti-tumorigenic 
actions of IbTX. BKCa/β-catenin complexes have been 
reported in cells of neural origin and in overexpression 
systems where β-catenin determines BKCa channel surface 
expression and clustering (19). However, in our experiments, 
IbTX downregulated β-catenin levels without significantly 
affecting the expression patterns of the BKCa channels. The 
observed differences were not due to the presence of BKCa 
splice variants with alterations in the β-catenin binding S10 
domain (19). Moreover, β-catenin-negative SK-BR-3 cells 
not only have BKCa channels present on the cell surface, but 
also respond to IbTX with β-catenin-independent increases 
in the expression of BKCa channels. These findings imply 
that breast cancer cells and neural cells/heterologous systems 
utilize disparate mechanisms to sustain BKCa channel expres-
sion. Canonical Wnt signaling may be a prerequisite for the 
antitumor effects of BKCa channel inhibitors; however, mech-
anisms other than BKCa/Wnt interactions may also mediate 
these effects. Similarly, differential regulation of HER-2/
neu oncoprotein levels by IbTX cannot be ascribed solely to 
previously reported HER-2neu/β-catenin complexes at least in 
SK-BR-3 cells (20).
In conclusion, the present study suggests that: i) BKCa chan-
nels function as oncogenes in β-catenin-positive breast cancer 
cells; ii) they direct their oncogenic input towards sustaining 
the tumorigenic ability of cancer cells; and iii) inhibitors of 
BKCa channels may modulate in vitro tumorigenesis via trans-
membrane depolarization.
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Figure 3. IbTX differentially regulates oncogenic pathways. (A) IbTX 
attenuated the HER-2/neu levels in the UACC893 cells (HER-2/neu, 
UACC893). SK-BR-3 cells express full length (HER-2/neu, SK-BR-3) and 
truncated (p95 HER-2/neu, SK-BR-3) oncoprotein isoforms with both being 
increased by IbTX. (B) IbTX downregulated the full length (β-catenin) 
but not truncated (trβ-catenin) β-catenin isoforms in the UACC893 and 
MDA-MB-231 cells. (C) In the UACC893 cells, IbTX attenuated phos-
phorylated (T308pAkt, UACC893) but not total Akt (Akt, UACC893). Both 
phosphorylated (T308pAkt, MDA-MB-231) and total (Akt, MDA-MB-231) 
Akt were decreased in the MDA-MB-231 cells with IbTX. In SK-BR-3 cells, 
phosphorylated (T308pAkt, SK-BR-3) and total (Akt, SK-BR-3) Akt increased 
at high IbTX concentrations. (D) GAPDH was used in the UACC893, MDA-
MB-231 and SK-BR-3 cell immunoblotting to ensure equal protein loading. 
IbTX, iberiotoxin.
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